Cancers 2011, 3(2), 2195-2213; doi:10.3390/cancers3022195

Harnessing Dendritic Cells for Tumor Antigen Presentation

1email and 2,* email
Received: 14 March 2011; in revised form: 14 April 2011 / Accepted: 19 April 2011 / Published: 26 April 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Dendritic cells (DC) are professional antigen presenting cells that are crucial for the induction of anti-tumor T cell responses. As a consequence, research has focused on the harnessing of DCs for therapeutic interventions. Although current strategies employing ex vivo-generated and tumor-antigen loaded DCs have been proven feasible, there are still many obstacles to overcome in order to improve clinical trial successes and offset the cost and complexity of customized cell therapy. This review focuses on one of these obstacles and a pivotal step for the priming of tumor-specific CD8+ and CD4+ T cells; the in vitro loading of DCs with tumor antigens.
Keywords: dendritic cell; tumor antigen; antigen presentation; antigen processing
PDF Full-text Download PDF Full-Text [229 KB, Updated Version, uploaded 27 April 2011 08:57 CEST]
The original version is still available [223 KB, uploaded 26 April 2011 18:16 CEST]

Export to BibTeX |

MDPI and ACS Style

Nierkens, S.; Janssen, E.M. Harnessing Dendritic Cells for Tumor Antigen Presentation. Cancers 2011, 3, 2195-2213.

AMA Style

Nierkens S, Janssen EM. Harnessing Dendritic Cells for Tumor Antigen Presentation. Cancers. 2011; 3(2):2195-2213.

Chicago/Turabian Style

Nierkens, Stefan; Janssen, Edith M. 2011. "Harnessing Dendritic Cells for Tumor Antigen Presentation." Cancers 3, no. 2: 2195-2213.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert